Healthcare News

RIAD, Saudi-Arabien, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Das King Faisal Specialist Hospital and Research Centre (KFSH) erweitert den Zugang der Patienten zu Notfallkompetenz über die Grenzen seiner...

ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST         Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk...

ORION OYJ        LEHDISTÖTIEDOTE        24.10.2026 KLO 9.30          Darolutamidi yhdessä ADT- ja sädehoidon kanssa vähensi 58 prosentilla syövän leviämisen tai kuoleman vaaraa potilailla, joilla...

IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and...

ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levelsConfirmed objective response...

The first patient dosing has been completed in phase 3 clinical study of JS203 (CD20/CD3 bsAb), in combination with chemotherapy in patients with R/R DLBCL

>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial...

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing...

Biochemist, entrepreneur and Just Blood founder Ryan El Hosseiny featured as “The Billboard Guy” in Nathan Fielder's documentary

SERB Pharmaceuticals announces positive results from the Post-Authorisation Efficacy Study (PAES) of Idefirix® (imlifidase),